Tysabri

Disease-modifying therapies, a group of treatments for people with relapsing-remitting multiple sclerosis (RRMS), work to stabilize patients’ cognitive functions just as they do their physical symptoms. Research, conducted over the course of a year, also reported no differences between two types of DMTs, Gilenya (fingolimod) and Tysabri (natalizumab). The study, “…

The Institute of Clinical and Economic Review (ICER) released the early draft of a paper intended to inform a future report evaluating the effectiveness and value of disease-modifying therapies for relapsing-remitting multiple sclerosis (RRMS). The paper, called a draft scoping document, is titled “Disease Modifying Therapies for Relapsing-Remitting Multiple Sclerosis: Effectiveness and…

Never having been offered, let alone received any disease modifying therapy, I can address the subject of disease modifying therapies, and their side effects, with complete impartiality. Of course, the reason for the lack of any medication is because none has yet been approved for use with MS patients who…

Results from the STRIVE study support the safety of natalizumab (Tysabri) as a therapy for multiple sclerosis (MS) patients. The study, “Natalizumab in Anti-JC Virus Seronegative Patients with Early Relapsing-Remitting Multiple Sclerosis: Interim Results from the STRIVE Study,” was recently presented at the 2016 Annual Meeting of the Consortium of Multiple Sclerosis…

Biogen, announced that TYSABRI, a drug developed to treat people with multiple sclerosis (MS) has received a positive opinion from the European Medicine Agency (EMA) recommending its approval to be used in people with elapsing-remitting multiple sclerosis (RRMS).

Mabthera (rituximab), a widely approved drug for treating lymphoma and/or rheumatoid arthritis, is highly effective in treating multiple sclerosis (MS), researchers reported in an observational study in Sweden, where Mabthera is increasingly being used outside of its approved indications to treat relapsing-remitting MS patients. The study, published in the journal…

A range of new multiple sclerosis (MS) data from Biogen will be revealed at the 68th annual meeting of the American Academy of Neurology (AAN) in Vancouver, Canada, on April 15–21. Presentations will include studies on Tecfidera (dimethyl fumarate), one of the most frequently used oral MS treatments worldwide, as well as several other…

Mice with experimental autoimmune encephalomyelitis (EAE), an animal model of multiple sclerosis (MS), were found to have milder symptoms if the target of natalizumab (Tysabri) — VLA4 — was absent on B-cells, preventing regulatory cells that might control immune processes from entering the brain. B-cells are increasingly thought to play…

Natalizumab (Tysabri) harnesses multiple sclerosis (MS) activity by targeting CD49, a molecule on the surface of immune cells. Now, researchers found that the drug reduces the factor on regulatory T-cells to a greater extent than on inflammatory T-cells — a mechanism that might explain disease exacerbation during treatment. The molecule under…

Certain therapies used to treat multiple sclerosis (MS) have been associated with opportunistic infections of the central nervous system, including progressive multifocal leukoencephalopathy (PML), a rare but often fatal brain disorder caused by the John Cunningham (JC) virus. The question of whether the risk for opportunistic infections to MS patients outweighs…

In a recent study of more than 1,200 patients with multiple sclerosis (MS), a research team reported that treatment with the drug natalizumab (Tysabri) could lead to a tenfold increase in the levels of blood antibodies associated with a virus causing a rare but severe brain disease known as progressive multifocal…

Multiple sclerosis (MS) patients treated with natalizumab have an increased risk of developing high levels of antibodies associated with a virus causing a rare, but often fatal, brain infection known as progressive multifocal leukoencephalopathy (PML), researchers reported. Their study, “Therapy with natalizumab is associated with high JCV seroconversion and rising JCV index values,”…

The Multiple Sclerosis Society of New Zealand (MSNZ) announced that PHARMAC has agreed with its request to finance two novel first-in-line therapies for relapsing-remitting forms of multiple sclerosis (MS), making them accessible to patients there. PHARMAC recently agreed to fund the two treatments, teriflunomide (Aubagio), supplied by Sanofi-Aventis NZ, and dimethyl fumarate (Tecfidera),…

Biogen Inc. recently reported that the Phase 3 ASCEND clinical trial study testing TYSABRI efficacy in patients with secondary progressive multiple sclerosis (SPMS) did not achieve its primary and secondary goals. According to the company, the comprehensive results of the study will be revealed at a future medical conference.

Biogen, a biotechnology company focused on innovative therapies for autoimmune disorders, neurodegenerative diseases and hematological conditions, recently announced that it will present new data on its multiple sclerosis (MS) portfolio of therapeutic agents at the upcoming 31st Congress of the European Committee for Treatment and Research in Multiple Sclerosis…

Two studies recently published in the journal Science Translational Medicine, revealed a possible new vaccine treatment for JC virus with important implications for multiple sclerosis (MS) treatment. The studies are entitled “JC polyomavirus mutants escape antibody-mediated neutralization” and “Broadly neutralizing human…

Researchers at Spedali Civili of Brescia in Italy recently published findings in the journal PLoS One that Biogen’s Tysabri (natalizumab) can improve cognitive impairment in patients with relapsing remitting multiple sclerosis (RRMS) over the course of at least three years. The study is entitled “Natalizumab Significantly…

The Pharmaceutical Management Agency (PHARMAC) is considering a funding proposal that includes five treatments for multiple sclerosis (MS), namely two key MS drugs,  Biogen‘s Tysabri and Novartis‘ Gilenya, that are not currently funded. PHARMAC is the New Zealand Crown agency that decides, on behalf of District…

Multiple sclerosis (MS) patients who are prescribed Tysabri have an increased risk to develop the rare, often fatal infection of the brain called progressive multifocal leukoencephalopathy (PML), according to a recent study. PML is caused by a common virus that infects blood cells and can be mobilized by popular RRMS drug Natalizumab,…

According to a study published in JAMA Neurology, multiple sclerosis patients are greatly benefited by Biogen Idec’s Tysabri (natalizumab) and tend to relapse if they discontinue treatment. Natalizumab had a protective effect on patients who were continuously treated with Tysabri beyond a 24-dose timepoint within the study,…

Biogen Idec is currently sponsoring a clinical trial evaluating its therapy Tysabri (natalizumab) in patients with secondary-progressive multiple sclerosis. Although relapse-remitting multiple sclerosis is more common and well-researched, the National Multiple Sclerosis Society estimates approximately half of relapse-remitting patients will transition to secondary-progressive within 19 years of diagnosis. The…